Transgene Biotek Ltd Stock Analysis

BSE: 526139 | NSE: | Hospital & Healthcare Services | Small Cap

BSE Share Price 06-Feb-2023 18:01
2.85 0.06 (2.15%)

DeciZen - Make an Informed Decision on Transgene Biotek

M-Cap below 100cr DeciZen not available

Transgene Biotek Price Chart

P/E Ratio ( SA) :
Market Cap :
21.6 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Transgene Biotek Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transgene Biotek Ltd is a below average quality company.

2. Is Transgene Biotek Ltd undervalued or overvalued?

The key valuation ratios of Transgene Biotek Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Transgene Biotek Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transgene Biotek Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Transgene Biotek:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Transgene Biotek Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % -0.6%-19%-9.3%-11.9%-17.2%-15.2%-24.7%-35.3%-49.5%-73.7%-
Value Creation Index -1.0-2.4-1.7-1.9-2.2-2.1-2.8-3.5-4.5NA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1510.
YoY Gr. Rt. %--93.5%-68.4%-41.9%55.6%-57.1%-41.7%-100%NA-47.1%-
Adj EPS -0.3-7-2.5-2.8-2.6-1.1-1.3-1.5-1.4-1.4-1.1
BVPS (₹) 492623.520.
Adj Net Profit -2-52.8-19-21.5-19.9-8.5-10-11-10.4-10.4-8
Cash Flow from Ops. 99.6-2.1-100-0.6-
Debt/CF from Ops. 0.2-6.2-15.2818692.9-15.8-5.374.1901.5125.2-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -43.4%-20.3%8.7%-47.1%
BVPS -144-135.3-120.6-104.8
Share Price -0.5% 5.6% -10.3% -20.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % -0.6-20.3-10.1-12.9-20.3-22.2-33-53.3-105.6-465.8468.1
Op. Profit Mgn % -5.6-185.4-480.9-623.1-910.9-1779.2-944.2-24147.1-307.2-531.8-155.2
Net Profit Mgn % -13.2-5376.3-6047.7-11864.4-7071.7-7161.3-14076-306601.7-6153.4-11998.4-5953.4
Debt to Equity
Working Cap Days 4,09028,75287,3921,34,72954,93775,0861,21,12724,16,57851,1631,00,2340
Cash Conv. Cycle 566,55519,84318,1021,1321551723,537522340

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 468.10%

Sales growth is good in last 4 quarters at 150.00%

Sales growth has been subdued in last 3 years 0.00%

Latest Financials - Transgene Biotek Ltd.

Standalone Consolidated
TTM EPS (₹) -1.1 -1.1
TTM Sales (₹ Cr.) 0.1 0.1
BVPS (₹.) -0.4 1.9
Reserves (₹ Cr.) -79 -62
P/BV -6.44 1.52
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 2.65 / 4.41
All Time Low / High (₹) 0.10 / 322.50
Market Cap (₹ Cr.) 21.6
Equity (₹ Cr.) 75.8
Face Value (₹) 10
Industry PE 60

Management X-Ray of Transgene Biotek :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Transgene Biotek

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Transgene Biotek Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Transgene Biotek on 06-Feb-2023 18:01 is : 2.85.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Feb-2023 18:01 the market cap of Transgene Biotek stood at ₹ 21.59.
The latest PE ratio of Transgene Biotek as of 06-Feb-2023 18:01 is 0.00.
The latest PB ratio of Transgene Biotek as of 06-Feb-2023 18:01 is -6.44
The 52-week high of Transgene Biotek is ₹ 4.41 and the 52-week low is ₹ 2.65.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Transgene Biotek is ₹ 0.14 ( Cr.) .

About Transgene Biotek Ltd

Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.

In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards.  Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology.   Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.

Product range of the company includes:

The company is engaged in manufacturing drugs for:

New Drug Delivery System (NDDS)

  • Oral Delivery of Insulin
  • Oral Delivery Hepatitis B Vaccine
  • Pegylation of Protein Drugs for Sustained Release


  • Tacrolimus 
  • Pegylated EPO 

Human Vaccines

  • Meningococcal Meningitis
  • Universal Meningococcal Meningitis
  • Haemophilus Influenza B-Hib
  • DTP+Hib+Hep B Combination
  •  Hepatitis A+B Combination 

Cancer Drugs/Oncology

  • Multiple Myeloma
  • Barrett's Esophageal Cancer
  • Colon Cancer
  • Breast Cancer  


Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now